Cost-effectiveness of ceftolozane/tazobactam for the treatment of complicated intraabdominal and urinary tract infections in Colombia
Ver / Descargar
Fecha
2020-01Autor(es)
Hernández, FabiánGarzón, Javier
Castañeda-Cardona, Camilo
Beltran, Claudia
Rojas, Mónica
Rosselli, Diego
Autor(es) Corporativo(s)
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Epidemiología Clínica y Bioestadística
Tipo
Artículo de revista
ISSN
0123-9392 / 2422-3794 (Electrónico)
Compartir este registro
Citación
Documentos PDF
Título en inglés
Cost-effectiveness of ceftolozane/tazobactam for the treatment of complicated intraabdominal and urinary tract infections in ColombiaAbstract
Objective: To evaluate the cost-effectiveness of ceftolozane/tazobactam + metronidazole (C/T+M) and ceftolozane/tazobactam (C/T) compared with 8 alternatives
used in the treatment of complicated intraabdominal infection (cIAI) and complicated urinary tract infection (cUTI) respectively.
Methods: A Monte Carlo simulation decision model was used for the estimation and comparison of treatment-related costs, and quality adjusted life years for
patients with cIAI treated with C/T+M in comparison with cefepime + metronidazole, ciprofloxacin + metronidazole, doripenem, levofloxacin + metronidazole,
meropenem, piperacillin/tazobactam, ceftazidime + metronidazole or imipenem/cilastatin and patients with cUTI treated with C/T in comparison with cefepime,
ciprofloxacin, doripenem, levofloxacin, meropenem, piperacillin/tazobactam, ceftazidime or imipenem/cilastatin. Local costs were estimated using base cases identified by experts and consulting local databases. Sensitivity values of the PACTS (Program to Assess Ceftolozane/Tazobactam Susceptibility) study in Latin America
were used in the model.
Results: C/T+M and C/T obtained incremental cost-effectiveness ratios (ICER) that were below the Colombian cost-effectiveness threshold (3 GDP per capita) in
most comparisons, and were dominated by meropenem, considering only gram-negative microorganisms. Sensitivity assessments were also carried out, in which
only the population with P. aeruginosa infections was considered, showing positive results for C/T+M and C/T (cost-effective or dominant with regards to all comparators).
Conclusions: C/T+M and C/T could be cost-effective alternatives in the treatment of CIAI and CUTI in Colombia, when there is an adequate and rational use of
antibiotics. The results of the sensitivity analyses showed dominance and cost-effectiveness with regards to every comparator in patients infected with P. aeruginosa
Keywords
CeftolozaneTazobactam
Cost-effectiveness
Urinary tract infections
Intraabdominal infections
Enlace al recurso
http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0123-93922020000100009Fuente
Infectio; Volumen 24 Número 1 , Páginas 9 - 14 (2020)
Estadísticas Google Analytics
Colecciones
- Artículos [682]